SecBot SecBot
6-K ·Filed May 15, 2026

RDY

DR REDDYS LABORATORIES LTD
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001575872-26-000334
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a positive product launch catalyst for Dr. Reddy's, establishing first-mover advantage in the Canadian generic semaglutide market. Monitor for subsequent launches in other G7 markets and any revenue guidance updates in upcoming quarterly filings. The GLP-1 franchise build-out supports long-term growth narrative.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.61
T+0 close · May 15, 2026 · via day close
Latest settled
−8.52%
T+60 · $12.45
Vs SPY
−13.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $13.61entry
  2. T+1 · 6mo ago −0.07%α −0.01% · $13.60
  3. T+5 · 6mo ago −0.07%α −1.04% · $13.60
  4. T+20 · 5mo ago −2.06%α −4.18% · $13.33
  5. T+60 · 3mo ago −8.52%α −13.04% · $12.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health Canada approval on April 28, 2026. The company is the first to receive approval for a generic semaglutide in Canada, which is also the first G7 country to authorize the product. This expands Dr. Reddy's GLP-1 portfolio and demonstrates its ability to rapidly commercialize complex peptides.

Key Facts

  • Dr. Reddy's launched generic Semaglutide Injection in Canada on May 15, 2026.
  • Health Canada Notice of Compliance (NOC) received on April 28, 2026.
  • Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection.
  • Canada is the first G7 country to grant market authorization for generic Semaglutide Injection.
  • Product is indicated for once-weekly treatment of type 2 diabetes in adults.
  • Available in 2 mg/pen and 4 mg/pen strengths (1.34 mg/ml concentration).
  • Follows recent launch in India under brand name Obeda.
  • CEO Erez Israeli highlighted GLP-1 therapies as a key focus area with active expansion across global markets.

Financial Impact

No specific revenue or financial figures disclosed in the filing. The launch expands addressable market in a high-growth GLP-1 category, but near-term financial contribution is unquantifiable from this filing alone.

revenuemarket share

Risk Factors

  • Competitive response from Novo Nordisk or other generic entrants could erode market share and pricing.
  • Regulatory or supply chain challenges in scaling production for additional markets.
  • Semaglutide is indicated only for type 2 diabetes in Canada; obesity indication not covered by this launch.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000334
Document: 0001575872-26-000334-index.html0001575872-26-000334
Document: 0001575872-26-000334.txt0001575872-26-000334

Track record

73 reports on RDY

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026